BNP Paribas Financial Markets’s Anika Therapeutics ANIK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$936K Buy
63,953
+16,732
+35% +$248K ﹤0.01% 3360
2026
Q1
$685K Sell
47,221
-24,960
-35% -$290K ﹤0.01% 3409
2025
Q4
$694K Buy
72,181
+56,918
+373% +$545K ﹤0.01% 3375
2025
Q3
$143K Buy
15,263
+13,960
+1,071% +$133K ﹤0.01% 4153
2025
Q2
$13.8K Sell
1,303
-7,763
-86% -$98K ﹤0.01% 4754
2025
Q1
$136K Sell
9,066
-5,382
-37% -$89.5K ﹤0.01% 3910
2024
Q4
$238K Buy
14,448
+11,607
+409% +$229K ﹤0.01% 3763
2024
Q3
$70.2K Sell
2,841
-149
-5% -$3.86K ﹤0.01% 3547
2024
Q2
$75.7K Sell
2,990
-19,250
-87% -$499K ﹤0.01% 3357
2024
Q1
$565K Buy
22,240
+3,217
+17% +$77.8K ﹤0.01% 2776
2023
Q4
$431K Buy
19,023
+4,852
+34% +$100K ﹤0.01% 2873
2023
Q3
$264K Buy
14,171
+4,224
+42% +$87.6K ﹤0.01% 3000
2023
Q2
$258K Sell
9,947
-6,928
-41% -$185K ﹤0.01% 2918
2023
Q1
$485K Buy
16,875
+7,379
+78% +$220K ﹤0.01% 2755
2022
Q4
$281K Sell
9,496
-8,457
-47% -$241K ﹤0.01% 2866
2022
Q3
$427K Buy
17,953
+12,961
+260% +$298K ﹤0.01% 3079
2022
Q2
$111K Sell
4,992
-296
-6% -$6.6K ﹤0.01% 3323
2022
Q1
$133K Sell
5,288
-4,180
-44% -$127K ﹤0.01% 3275
2021
Q4
$339K Sell
9,468
-5,705
-38% -$228K ﹤0.01% 3200
2021
Q3
$646K Buy
15,173
+8,616
+131% +$355K ﹤0.01% 2629
2021
Q2
$284K Sell
6,557
-1,462
-18% -$62.3K ﹤0.01% 2770
2021
Q1
$327K Buy
8,019
+5,467
+214% +$207K ﹤0.01% 2803
2020
Q4
$116K Sell
2,552
-971
-28% -$36.9K ﹤0.01% 3141
2020
Q3
$125K Sell
3,523
-13,689
-80% -$494K ﹤0.01% 2993
2020
Q2
$649K Sell
17,212
-15,031
-47% -$495K ﹤0.01% 1983
2020
Q1
$932K Buy
32,243
+28,747
+822% +$1.16M ﹤0.01% 1958
2019
Q4
$181K Buy
3,496
+990
+40% +$57.5K ﹤0.01% 3002
2019
Q3
$138K Buy
2,506
+964
+63% +$49.5K ﹤0.01% 2943
2019
Q2
$62.6K Sell
1,542
-1,349
-47% -$49.2K ﹤0.01% 3288
2019
Q1
$87.4K Buy
2,891
+2,257
+356% +$77.3K ﹤0.01% 3203
2018
Q4
$21.3K Buy
634
+135
+27% +$4.87K ﹤0.01% 3087
2018
Q3
$21K Sell
499
-1,227
-71% -$48.5K ﹤0.01% 3397
2018
Q2
$55.2K Sell
1,726
-3,003
-64% -$124K ﹤0.01% 3076
2018
Q1
$235K Sell
4,729
-9,364
-66% -$529K ﹤0.01% 2704
2017
Q4
$760K Buy
14,093
+6,820
+94% +$377K ﹤0.01% 2178
2017
Q3
$422K Buy
7,273
+2,958
+69% +$155K ﹤0.01% 2076
2017
Q2
$213K Buy
4,315
+126
+3% +$5.8K ﹤0.01% 2417
2017
Q1
$182K Sell
4,189
-302
-7% -$14.4K ﹤0.01% 2259
2016
Q4
$220K Buy
4,491
+2,227
+98% +$103K ﹤0.01% 2158
2016
Q3
$108K Sell
2,264
-2,421
-52% -$120K ﹤0.01% 2063
2016
Q2
$251K Buy
4,685
+2,184
+87% +$103K ﹤0.01% 1815
2016
Q1
$112K Sell
2,501
-337
-12% -$13.7K ﹤0.01% 1751
2015
Q4
$108K Sell
2,838
-332
-10% -$12.7K ﹤0.01% 2284
2015
Q3
$101K Buy
3,170
+1,953
+160% +$68.1K ﹤0.01% 2389
2015
Q2
$40.2K Buy
1,217
+866
+247% +$30.9K ﹤0.01% 2621
2015
Q1
$14.5K Buy
+351
New +$14.2K ﹤0.01% 2541
2014
Q4
Sell
-1,070
Closed -$39.2K 2044
2014
Q3
$39.2K Buy
1,070
+1,018
+1,958% +$44K ﹤0.01% 2732
2014
Q2
$2.41K Buy
52
+9
+21% +$400 ﹤0.01% 2995
2014
Q1
$1.84K Sell
43
-136
-76% -$5.05K ﹤0.01% 2687
2013
Q4
$6.83K Buy
+179
New +$5.52K ﹤0.01% 2898

Other funds holding ANIK

BNP Paribas Financial Markets's ANIK Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Anika Therapeutics (ANIK) stake by 35% in Q2 2026, buying an estimated $248K and bringing the position to 63,953 shares worth $936K. The position accounts for ﹤0.01% of the portfolio, ranked #3360.

BNP Paribas Financial Markets first reported a position in ANIK in Q4 2013 and has held it in 50 quarters since. 123 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • BNP Paribas Financial Markets held 63,953 shares of Anika Therapeutics worth $936K as of Q2 2026.
  • BNP Paribas Financial Markets bought 16,732 Anika Therapeutics shares in Q2 2026, an estimated $248K.
  • Anika Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3360 holding.
  • BNP Paribas Financial Markets first reported a position in Anika Therapeutics in Q4 2013 and has held it in 50 quarters since.
  • 123 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.